The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Theseus Pharmaceuticals has an asset utilization ratio of 8.77 percent. This suggests that the company is making $0.0877 for each dollar of assets. An increasing asset utilization means that Theseus Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Theseus Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Theseus Pharmaceuticals this year
Annual and quarterly reports issued by Theseus Pharmaceuticals are formal
financial statements that are published yearly and quarterly and sent to Theseus stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Theseus Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Is Theseus a risky opportunity?
Let's check the volatility. Theseus is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Theseus (NASDAQ:THRX) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of a Theseus Pharmaceuticals stock makes you a part-owner of that company.
Theseus Pharmaceuticals Current Consensus
Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Theseus Pharmaceuticals. The Theseus consensus assessment is calculated by taking the average estimates from all of the analysts covering Theseus Pharmaceuticals
| Strong Buy | 0 | 0.0 |
| Buy | 0 | 0.0 |
| Hold | 3 | 60.0 |
| Sell | 1 | 20.0 |
| Strong Sell | 1 | 20.0 |
Our perspective of the current Theseus Pharmaceuticals rise
Theseus Pharmaceuticals current standard deviation rises over 9.07.
As of the 18th of March 2022, Theseus Pharmaceuticals has the Coefficient Of Variation of 2630.94,
semi deviation of 7.68, and Risk Adjusted Performance of 0.0489. In relation to
fundamental indicators, the
technical analysis model makes it possible for you to check existing technical drivers of Theseus Pharmaceuticals, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen
technical drivers for Theseus Pharmaceuticals, which can be compared to its competition. Please validate
Theseus Pharmaceuticals semi deviation,
jensen alpha, as well as the
relationship between the Jensen Alpha and
semi variance to decide if Theseus Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 14.51 per share. Given that Theseus Pharmaceuticals has
jensen alpha of 0.4645, we advise you to double-check Theseus Pharmaceuticals's current market performance to make sure the company can sustain itself at a future point.
The Current Takeaway on Theseus Pharmaceuticals Investment
While some firms under the biotechnology industry are still a bit expensive, Theseus Pharmaceuticals may offer a potential longer-term growth to investors. To conclude, as of the 18th of March 2022, we believe that Theseus Pharmaceuticals is currently
overvalued with
very high chance of bankruptcy in the next two years. Our current 90 days 'Buy-vs-Sell' recommendation on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Theseus Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
